Surrogate end points in clinical research: Hazardous to your health

Obstetrics and Gynecology

Volumn 105, Issue 5, 2005, Pages 1114-1118

  Grimes, David A ^a   Schulz, Kenneth F ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; SPERMICIDAL AGENT;

BONE DENSITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONDOM; DISEASE MARKER; FRACTURE; HEALTH HAZARD; HUMAN; LABORATORY TEST; MEDICAL ERROR; MEDICAL LITERATURE; MORTALITY; ORAL CONTRACEPTION; OUTCOMES RESEARCH; POSTCOITAL TEST; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VEIN THROMBOSIS;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS; ENDPOINT DETERMINATION; FEMALE; GYNECOLOGY; HEART FAILURE, CONGESTIVE; HUMANS; MALE; OBSTETRICS; OSTEOPOROSIS; PREGNANCY; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 17644412369     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000157445.67309.19     Document Type: Editorial

References (38)

1. Altman DG. The scandal of poor medical research. BMJ 1994;308:283-4.
2. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
3. Holloway RG, Dick AW. Clinical trial end points: on the road to nowhere? Neurology 2002;58:679-86.
4. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
5. Senn S. Statistical issues in drug development. Chichester, England: John Wiley & Sons, 1997.
6. Albert JM, Ioannidis JP, Reichelderfer P, Conway B, Coombs RW, Crane L, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop. Stat Med 1998;17:2435-62.
7. Levin B. Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention. J Natl Cancer Inst 2003;95:697-9.
8. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2002;2:19-27.
9. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003;3:16.
10. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
11. Riggs BL, Hodgson SF, O’Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-9.
12. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
13. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1980;2:379-85.
14. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
15. Hampton JR, van Veldhuisen DJ, Kleber FX, Cowley AJ, Ardia A, Block P, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997;349:971-7.
16. Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software.
17. Baggett B, Nash HA. Effects of contraceptive steroids on serum lipoproteins and cardiovascular disease scrutinized at workshop in Bethesda. Contraception 1980;21:115-20.
18. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
19. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
20. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston (MA): Little, Brown and Company; 1991.
21. Furedi A. The public health implications of the 1995 “pill scare”. Hum Reprod Update 1999;5:621-6.
22. Runnebaum B. The androgenicity of oral contraceptives: the young patient’s concerns. Int J Fertil 1992;37(suppl 4):211-7.
23. Stedman’s Medical Dictionary. 27th edition. Philadelphia (PA): Lippincott Williams & Wilkins; 2000.
24. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990;41:345-52.
25. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482-90.
26. van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormone-binding globulin: a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004;190:332-7.
27. Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982;142:781-90.
28. Winkler UH. Blood coagulation and oral contraceptives: a critical review. Contraception 1998;57:203-9.
29. Comp PC. Thrombophilic mechanisms of OCs. Int J Fertil Womens Med 1997;suppl 1:170-6.
30. Sangi-Haghpeykar H, Poindexter AN 3rd, Levine H. Sperm transport and survival post-application of a new spermicide contraceptive. Advantage 24 Study Group. Contraception 1996;53:353-6.
31. Griffith CS, Grimes DA. The validity of the postcoital test. Am J Obstet Gynecol 1990;162:615-20.
32. Oei SG, Helmerhorst FM, Bloemenkamp KW, Hollants FA, Meerpoel DE, Keirse MJ. Effectiveness of the postcoital test: randomised controlled trial. BMJ 1998;317:502-5.
33. Potter WD, de Villemeur M. Clinical breakage, slippage and acceptability of a new commercial polyurethane condom: a randomized, controlled study. Contraception 2003;68:39-45.
34. Walsh TL, Frezieres RG, Peacock K, Nelson AL, Clark VA, Bernstein L. Evaluation of the efficacy of a nonlatex condom: results from a randomized, controlled clinical trial. Perspect Sex Reprod Health 2003;35:79-86.
35. Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol 2003;101:539-47.
36. U.S. Food and Drug Administration. Black box warning added concerning long-term use of Depo-Provera contraceptive injection. FDA Talk Paper T04-50: November 17, 2004. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html. Retrieved January 31, 2005.
37. Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004;292:2105-14.
38. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin 2004;20:341-9.